IC
MRNS

Ikarian Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Ikarian Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-212,200
Closed -$1.92M – 161
2024
Q1 		$1.92M Buy
+212,200
New +$2.06M 0.21% 90

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital's MRNS Position: Q4 2024 in Review

Ikarian Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 706,154 shares — an estimated $1.24M sold.

Ikarian Capital first reported a position in MRNS in Q2 2023 and held it in 6 quarters. The position peaked at $8.11M in Q4 2023. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Ikarian Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Ikarian Capital sold 706,154 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $1.24M.
  • Ikarian Capital first reported a position in Marinus Pharmaceuticals, Inc in Q2 2023 and held it in 6 quarters.
  • Ikarian Capital's Marinus Pharmaceuticals, Inc position peaked at $8.11M in Q4 2023.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Ikarian Capital's 13F filing for Q4 2024, filed 14 Feb 2025.